The department store retailer said revenue for the year ahead will range from a 2% decline to a 1% gain compared with the previous year.
Continue readingCategory Archives: Uncategorized
Abercrombie & Fitch beats holiday estimates as sales soar again, helped by higher prices
Abercrombie & Fitch has been on a rollercoaster of growth over the last year and Wall Street will be keen to see if it can […]
Continue readingRussian oligarch’s yacht is costing U.S. taxpayers close to $1 million a month
The Justice Department is seeking permission to sell a 348-foot yacht called Amadea, which it seized in 2022, alleging it was owned by Suleiman Kerimov.
Continue readingTarget launches paid membership program as it chases new revenue streams
Target is following the playbook of Amazon and Walmart, which already have similar programs.
Continue readingBiden says Medicare should negotiate prices for at least 50 drugs each year, up from a target of 20
The proposal is one of several new health-care policy proposals that Biden will outline during his State of the Union address Thursday.
Continue readingFoot Locker shares plunge nearly 30% as retailer posts holiday loss, delays key financial target
Foot Locker reported earnings as CEO Mary Dillon leads the legacy retailer through an ambitious turnaround. But some analysts say it has gone too slowly.
Continue readingWhy private equity has been involved in every recent bank deal
New York Community Bank’s $1 billion-plus capital raise is the latest example of private equity players coming to rescue a regional bank.
Continue readingSaturday morning cartoons, streaming anytime: Why kids content is vital to subscriber growth
The unique thing about kids content is that streamers don’t need a lot of it to keep kids occupied.
Continue readingA handful of space companies are running out of cash and time. Here are three at risk
While many space companies battened the hatches to survive, a few publicly-traded names are running on fumes.
Continue readingMerck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.
Continue reading